Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...
Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...
The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback